Mundipharma's REZZAYO (Rezafungin) Meets Primary Endpoint in Phase III ReSPECT Trial for Fungal Disease Prevention

Key Takeaways

• REZZAYO (rezafungin) successfully met primary endpoint for fungal-free survival at Day 90 in Phase III ReSPECT trial
• Trial evaluated prevention of invasive fungal diseases in adult patients undergoing allogeneic stem cell transplantation
• Results meet both FDA and EMA regulatory standards, positioning drug for potential approval submissions

---

Mundipharma Reports Breakthrough Results for Antifungal Prophylaxis

Mundipharma announced positive topline results from its global Phase III ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for preventing invasive fungal diseases (IFDs) in adult patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT).

The ReSPECT study successfully met its primary endpoint for fungal-free survival at Day 90, meeting both US Food and Drug Administration (FDA) and European Medicines Agency (EMA) regulatory standards. This represents a significant milestone for patients at high risk of life-threatening fungal infections following stem cell transplantation.

Clinical Significance and Market Impact

Invasive fungal diseases pose a serious threat to immunocompromised patients, particularly those undergoing HSCT procedures. Current prophylactic treatments often require daily dosing and can have significant side effects, creating an unmet medical need for more convenient and effective options.

REZZAYO’s once-weekly dosing regimen could offer substantial advantages over existing daily antifungal prophylaxis options, potentially improving patient compliance and reducing healthcare burden. The drug’s novel mechanism as a next-generation echinocandin positions it as a potentially best-in-class treatment option.

Regulatory Pathway Forward

With positive Phase III results now in hand, Mundipharma is expected to prepare regulatory submissions to major health authorities. The company’s ability to meet both FDA and EMA standards in the same trial streamlines the path toward potential approvals in key markets.

The successful completion of ReSPECT adds to REZZAYO’s clinical profile, which already includes positive data in treatment settings. This prophylaxis indication could significantly expand the drug’s commercial potential in the antifungal market.

Industry Context

The antifungal prophylaxis market has seen limited innovation in recent years, with most available options requiring frequent dosing. REZZAYO’s differentiated profile could capture significant market share if approved, particularly given the growing number of HSCT procedures performed globally.

Mundipharma has not yet disclosed detailed efficacy and safety data from the trial, but plans to present full results at upcoming medical conferences and in peer-reviewed publications.

---

Frequently Asked Questions

What does this mean for stem cell transplant patients?

If approved, REZZAYO could provide a more convenient once-weekly option to prevent serious fungal infections, compared to current daily treatments, potentially improving patient outcomes and quality of life.

When will REZZAYO be available for fungal disease prevention?

Mundipharma will need to submit regulatory applications based on these results. Approval timelines typically range from 6-12 months after submission, depending on regulatory review processes.

How does REZZAYO compare to existing antifungal prevention treatments?

REZZAYO offers once-weekly dosing versus daily dosing required by most current options, and as a next-generation echinocandin, it may provide improved efficacy and tolerability profiles.